Alumis in Spotlight After Psoriasis Win Ahead of Investor Conference

SOUTH SAN FRANCISCO, CA – March 02, 2026 – Alumis Inc. is preparing for a high-stakes presentation at the Leerink Partners Global Healthcare Conference next week, where CEO Martin Babler is expected to address investors. While conference appearances are routine, this fireside chat on March 9th comes at a pivotal moment for the biopharma company, which is riding a wave of clinical success and heightened market expectations following a landmark year.

Investors and analysts will be listening closely for insights into the company's strategy to capitalize on its recent triumphs, particularly the blockbuster results for its lead drug candidate, and how it plans to navigate an increasingly competitive landscape for immune-mediated disease therapies.

Riding a Wave of Clinical Success

Alumis (Nasdaq: ALMS) captured Wall Street's attention in January 2026 with the announcement of positive topline results from its ONWARD1 and ONWARD2 Phase 3 trials. The studies evaluated envudeucitinib, an oral therapy for patients with moderate-to-severe plaque psoriasis. The news was a significant validation of the company's lead asset, triggering a remarkable 132% surge in its stock price and cementing its position as a formidable player in the immunology space.

Envudeucitinib belongs to a promising class of drugs known as tyrosine kinase 2 (TYK2) inhibitors. These therapies work by selectively modulating immune-signaling pathways implicated in a range of autoimmune disorders. By offering a more targeted mechanism than older Janus kinase (JAK) inhibitors, TYK2 drugs aim to provide strong efficacy with a more favorable safety profile, reducing the risk of broader immunosuppression.

Following the clinical data release, Alumis successfully executed an upsized public offering of its common stock, leveraging the powerful market momentum to strengthen its balance sheet. This financial maneuver, combined with cash from a 2025 merger with Acelyrin, has reportedly extended the company's operational runway into 2027, providing critical resources to advance its ambitious pipeline.

A Pipeline Built on Precision Targeting

Beyond the headline-grabbing psoriasis results, Alumis is advancing a multi-asset pipeline built on what it describes as a proprietary data analytics platform and precision approach. The company's strategy hinges on developing potential best-in-class therapies for diseases with significant unmet needs.

• Envudeucitinib: With Phase 3 success in psoriasis secured, Alumis intends to pursue regulatory submissions. The company is also exploring the drug's potential in other systemic immune-mediated disorders, with ongoing Phase 2 trials in systemic lupus erythematosus (SLE) and non-infectious uveitis. Success in these indications could dramatically expand the drug's market potential.

• A-005: Representing a new frontier for the company, A-005 is a brain-penetrant TYK2 inhibitor designed to treat neuroinflammatory and neurodegenerative diseases. Having successfully completed a Phase 1 study that demonstrated its ability to cross the blood-brain barrier and engage its target, A-005 is a novel asset. Alumis is expected to initiate a Phase 2 trial in patients with multiple sclerosis (MS) in the first half of 2026, a move that could position it as a first-in-class therapy for neurological conditions driven by inflammation.

• Lonigutamab: Acquired through the Acelyrin merger, lonigutamab is a subcutaneously delivered antibody therapy for thyroid eye disease (TED). It aims to challenge established intravenous treatments, like Amgen's Tepezza, by offering a more convenient administration route. While preliminary data showed comparable efficacy, some analysts remain skeptical about its ability to significantly differentiate itself in a market with entrenched and developing competitors.

Navigating a Crowded Immunology Landscape

The market for immune-mediated diseases is intensely competitive, and Alumis faces rivals on multiple fronts. In the TYK2 inhibitor space for psoriasis, its primary competitor is Bristol-Myers Squibb's Sotyktu (deucravacitinib), the first drug in this class to receive FDA approval. Sotyktu generated $190 million in U.S. sales in 2024, demonstrating a growing market. Alumis is positioning envudeucitinib as a potential best-in-class option, hoping that its clinical data will demonstrate superior efficacy or safety.

Other pharmaceutical giants, including Takeda and Galapagos, are also developing their own TYK2 inhibitors, underscoring the high level of interest and competition in this therapeutic area. The company's success will depend not only on regulatory approval but also on its ability to effectively communicate its clinical advantages to physicians and payers.

The challenge is similar in the TED market, where lonigutamab's subcutaneous delivery is its main point of differentiation. Convincing the market of its value against established intravenous therapies will be a key commercial hurdle.

Wall Street's Bullish Bet

Since its IPO in June 2024, in which Leerink Partners served as a joint book-running manager, Alumis has garnered a largely bullish consensus from Wall Street. Most analysts covering the stock hold a "Buy" or "Strong Buy" rating, with average 12-month price targets suggesting significant upside from its recent trading levels around $30 per share. This optimism is overwhelmingly fueled by the potential of envudeucitinib to become a leading therapy in psoriasis and possibly lupus.

The upcoming fireside chat offers CEO Martin Babler a platform to reinforce this positive narrative. Investors will be eager for more detail on the regulatory submission timeline for envudeucitinib, commercial launch preparations, and progress updates on the Phase 2 programs for both envudeucitinib and A-005. The presentation will be a critical opportunity for management to lay out its strategic vision for converting its recent clinical victories into long-term commercial success and shareholder value.